Co-promotion and Co-marketing Partnering Terms & Agreements


#100027

762pages

Current Partnering

$ 2695

In Stock


The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access tthe co-promotion and co-marketing partnering agreements entered intby the worlds leading biopharma companies.

This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of co-promotion and co-marketing agreements from 2007 tearly 2012.

The report provides a detailed understand and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option tco-promote/market the resultant product of the research collaboration. There are alsnumerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order tmaximize a products presence in the marketplace.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight intthe negotiation process in terms of what you can expect tachieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases dnot.

This report contains a comprehensive listing of all co-promotion and co-marketing deals announced since 2007 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links tonline copies of actual co-promotion and co-marketing contract documents as submitted tthe Securities Exchange Commission by companies and their partners.

Contract documents provide the answers tnumerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability tderive value from the deal.

The initial chapters of this report provide an orientation of co-promotion and co-marketing dealmaking and business activities. 

Chapter 1 provides an introduction tthe report, whilst 

Chapter 2 provides an analysis of the trends in co-promotion and co-marketing as well as a discussion on the merits of each type of deal.

Chapters 3 and 4 provide an overview of the structure of co-promotion and co-marketing deals, respectively. Each chapter includes numerous case studies tenable understanding of both pure co-promotion/marketing deals and multicomponent deals where co-promotion/marketing forms a part.

Chapters 5 and 6 provide a review of the leading co-promotion and co-marketing deals since 2007, respectively. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access tthe contract via the Current Agreements deals and alliances database.

Chapter 7 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of co-promotion and co-marketing contract deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database tan online version of the actual contract document, providing easy access teach contract document on demand.

Chapters 8 and 9 provide a comprehensive and detailed review of co-promotion and co-marketing deals signed and announced since 2007. Each chapter is organized by A-Z, stage of development at signing, and therapeutic area. Each deal title links via Weblink tan online version of the actual contract document, providing easy access teach contract document on demand.

Key benefits

  • Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics provides the reader with the following key benefits:
  • In-depth understanding of co-promotion and co-marketing deal trends since 2007
  • Analysis of the structure of co-promotion and co-marketing agreements with numerous real life case studies
  • Comprehensive access tover 1,000 actual co-promotion and co-marketing deals entered intby the world’s biopharma companies
  • Detailed access tactual co-promotion and co-marketing contracts entered intby the leading fifty bigpharma companies
  • Insight intthe terms included in a co-promotion and co-marketing agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence tassess suitability of your proposed deal terms for partner companies

Report scope

  • Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics is intended tprovide the reader with an in-depth understanding of the co-promotion and co-marketing trends and structure of deals entered intby leading biopharma companies worldwide.
  • Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics includes:
  • Trends in co-promotion and co-marketing dealmaking in the biopharma industry since 2007
  • Analysis of co-promotion and co-marketing deal structure
  • Case studies of real-life co-promotion and co-marketing deals
  • Access tover 1,000 co-promotion and co-marketing deal records
  • Detailed access tactual co-promotion contract documents
  • The leading co-promotion and co-marketing deals by value since 2007
  • Most active co-promotion and co-marketing dealmakers since 2007
  • The leading co-promotion and co-marketing partnering resources

In Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Therapeutic area

Each deal title links via Weblink tan online version of deal record as found in the Current Agreements deals and alliances database, providing easy access teach deal record on demand.

The report alsincludes numerous table and figures that illustrate the trends and activities in co-promotion and co-marketing dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs tknow about co-promotion and co-marketing as an opportunity tparticipate in the commercialization of either candidate compounds in development or products already on the market.

therapeutic area. Each deal title links via Weblink tan online version of the actual contract document, providing easy access teach contract document on demand.
The report alsincludes numerous table and figures that illustrate the trends and activities in co-promotion and co-marketing dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs tknow about co-promotion and co-marketing as an opportunity tparticipate in the commercialization of either candidate compounds in development or products already on the market.

The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive access trecords for over 1,000 co-promotion and co-marketing deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise co-promotion and co-marketing rights granted or optioned?
  • What is actually granted by the agreement tthe partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Whis responsible for commercialization?
  • Whis responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes tbe resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear tdiffer from partner tpartner or deal type tdeal type?
  • Which jurisdiction does the company insist upon for agreement law?